M4 macrophages are a CXCL4-conditioned macrophage state first defined in human monocyte-derived macrophages and subsequently investigated in the context of atherosclerotic plaques. They are best known for reduced expression of the hemoglobin-haptoglobin scavenger receptor CD163 and for a transcriptional program that differs from canonical interferon/LPS-driven M1 and IL-4/IL-13-driven M2 models. Because M4 biology is strongly shaped by stimulus, donor, tissue, time, and assay platform, a rigorous study treats "M4" as an operational phenotype supported by convergent evidence rather than as a permanent lineage label.

Fig.1 Several major macrophage subtypes.^1,2

Creative Biolabs provides macrophage-focused research capabilities that can be assembled into a fit-for-purpose workflow for CXCL4-conditioned macrophage studies. A project may combine source selection, macrophage differentiation, polarization controls, multiparameter phenotyping, secretome analysis, phagocytic readouts, pathway perturbation, and disease-relevant co-culture. The goal is not simply to assign a name to a cell population, but to determine whether CXCL4 produces a reproducible state with a meaningful function in the biological system under study.

Understanding the M4 Macrophage Phenotype

Macrophages do not move between a small number of discrete, universally conserved boxes. They continuously integrate soluble mediators, extracellular matrix signals, lipids, dying cells, microbial products, hypoxia, mechanical cues, and communication from neighboring cells. The familiar M1/M2 framework remains useful for experimental orientation, but it does not encompass the range of states observed in tissues or generated by defined stimuli. M4 belongs to a broader stimulus-centered nomenclature in which the inducing condition is part of the definition.

In the original human in vitro system, the platelet-derived chemokine CXCL4, also known as platelet factor 4, induced a macrophage transcriptome distinct from established M1 and M2 reference conditions. The M4 label therefore describes a CXCL4-conditioned state, not the fourth point on a linear activation scale. This distinction matters: a cell can share selected features with M4 macrophages while retaining programs imposed by its tissue of origin or by simultaneous exposure to other mediators.

The clearest practical implication is that no single marker proves M4 identity. CD163 downregulation is historically central, but CD163 can also vary with differentiation method, inflammatory stress, glucocorticoids, heme exposure, and tissue context. MMP7 and S100A8 have been used with CD68 and the absence or low abundance of CD163 to identify M4-like macrophages in human vascular lesions. Even this combination should be interpreted alongside the CXCL4 exposure history, a broader marker panel, morphology, transcriptional data, and a functional readout.

Where M4 Fits within the Macrophage Activation Spectrum

M4 macrophages are frequently compared with M0, M1, and M2 macrophages because those controls help reveal what is specific to CXCL4 conditioning. M0 is a differentiation baseline rather than a biologically inactive cell. M1-like controls generally emphasize inflammatory and antimicrobial programs, whereas M2-like controls emphasize selected tissue-repair, scavenging, or type 2 immune features. M4 cells may show inflammatory, proteolytic, and remodeling-associated properties, yet they should not be described as merely another M1 subtype.

A better design uses a reference panel rather than a binary comparator. For example, donor-matched macrophages can be maintained as a baseline control, exposed to CXCL4, exposed to a defined M1-like condition, and exposed to a defined M2-like condition. The resulting data can then be analyzed as multidimensional distances among conditions. This approach prevents a marker that changes in several activation states from being misinterpreted as uniquely diagnostic of M4 biology.

CXCL4-Driven Induction and Biological Context

CXCL4 is abundant in platelet alpha granules and is released during platelet activation. It binds glycosaminoglycans and can form localized gradients on vascular and extracellular matrix surfaces. In atherosclerosis, platelet activation, endothelial dysfunction, leukocyte recruitment, lipid retention, and tissue remodeling coexist, creating a plausible setting in which monocytes and macrophages encounter CXCL4 together with many other cues. The resulting plaque macrophage state is therefore likely to reflect integrated signaling rather than CXCL4 in isolation.

In vitro M4 induction usually begins with purified human monocytes or monocyte-derived macrophages, a defined differentiation regimen, and subsequent CXCL4 exposure. The exact concentration, exposure duration, media formulation, serum source, plate material, cell density, and timing relative to differentiation can materially affect the response. Published protocols are useful starting points, but a new system should include dose and time-course work rather than assuming that one condition will transfer unchanged across laboratories.

A Signal-to-State Model for M4 Research

Mechanistically, CXCL4 responses have been linked to a signaling environment that differs from conventional chemokine-receptor models, and the identity of the relevant receptor complexes remains context dependent. It is therefore safer to test pathway dependence experimentally than to treat one receptor as universally required. Neutralizing reagents, receptor-blocking strategies, glycosaminoglycan competition, gene perturbation, and downstream phosphoprotein or transcription-factor measurements can help distinguish direct CXCL4 effects from secondary autocrine signaling.

Time is another biological variable. Early signaling and transcriptional responses may precede stable changes in surface proteins or secreted mediators, while prolonged exposure may alter survival, differentiation, or metabolic state. A useful experiment separates immediate signaling, intermediate gene expression, and later phenotype or function. Sampling only one late time point can miss the trajectory and can make a transient response look constitutive.

M4 Macrophage Markers and Phenotyping Strategy

A robust M4 panel combines identity, exclusion, activation, and functional markers. General macrophage markers confirm that the analyzed cells remain within the intended myeloid population. M4-associated markers test the CXCL4-conditioned program. Comparator markers determine whether the cells have shifted toward other activation references. Viability and sample-quality measurements protect the analysis from artifacts caused by cell loss, enzymatic dissociation, or nonspecific staining.

Principles for Interpreting an M4 Marker Panel

• Define the inducing condition and sampling time in the phenotype name, for example M(CXCL4, 48 h), when sufficient protocol detail is available.
• Compare each donor with a matched baseline and with biologically relevant M1-like and M2-like reference conditions.
• Use at least two M4-associated dimensions and one functional readout; do not classify cells from CD163 loss alone.
• Report both the proportion of positive cells and expression intensity where the assay supports both measures.
• Confirm that apparent marker changes are not explained by selective death, altered macrophage purity, or batch-specific staining.
• For tissue studies, include spatial context and distinguish macrophages from closely related monocytes, dendritic cells, and neutrophils.

Protein and RNA measurements should be treated as complementary. A transcriptional increase does not guarantee increased surface abundance or secretion, and stored or shed proteins can complicate interpretation. Orthogonal confirmation is particularly valuable for CD163 because membrane expression, soluble CD163 release, and transcript abundance represent different biological layers. Likewise, MMP7 activity may be more informative than abundance when the research question concerns matrix remodeling.

Functional Features of CXCL4-Conditioned Macrophages

Scavenging, Hemoglobin Handling, and CD163

CD163 participates in the uptake of hemoglobin-haptoglobin complexes and is often associated with macrophage programs that limit oxidative damage in hemorrhagic or heme-rich environments. CXCL4-mediated CD163 downregulation therefore provides a mechanistic bridge between phenotype and potential loss of a protective scavenging function. The magnitude and consequence of that change should be measured directly, because receptor abundance alone does not establish the rate of ligand uptake, heme metabolism, or oxidative injury.

A functional module can pair CD163 measurements with labeled hemoglobin-haptoglobin uptake, intracellular heme or iron handling, oxidative-stress markers, and expression of heme-responsive genes. Controls should account for serum proteins and for other scavenger receptors that may compensate. In vascular studies, this module can be combined with lipid loading to ask whether heme and lipid stress interact in CXCL4-conditioned cells.

Lipid Uptake and Foam-Cell Biology

M4 macrophages have been studied in atherosclerosis because plaque macrophages encounter modified lipoproteins and may become lipid-laden foam cells. CXCL4 can interact with vascular surfaces and has been implicated in processes that influence lipoprotein retention and macrophage behavior. However, foam-cell formation is not a universal defining property of M4 identity. Lipid uptake depends on lipoprotein preparation, oxidation state, concentration, exposure time, donor metabolism, and the balance among uptake, esterification, storage, efflux, and cell death.

A well-resolved experiment measures more than total fluorescence from a labeled lipid. Useful readouts include uptake kinetics, neutral-lipid accumulation, cholesterol esterification, lipid-droplet morphology, cholesterol efflux to defined acceptors, and cell viability. Comparing these endpoints across M(CXCL4), baseline, and other polarization controls reveals whether CXCL4 changes entry, processing, or export rather than simply changing the final lipid burden.

Inflammatory and Proteolytic Activity

The M4-associated program includes inflammatory and proteolytic features that may be relevant to plaque evolution. MMP7 provides one connection to extracellular matrix remodeling, while S100A8 points to an alarmin-rich myeloid program in selected contexts. These molecules are not exclusive to M4 macrophages and can be influenced by contaminating cells, acute stress, or tissue digestion. Their value increases when they co-occur with macrophage identity, CXCL4 exposure, and a broader state signature.

Secretome profiling can test whether the molecular phenotype produces a biologically meaningful signaling output. Targeted ELISAs are efficient when the hypothesis is narrow, whereas multiplex cytokine and chemokine analysis is better suited to discovery or comparison among polarization conditions. Measurements should be normalized to viable cell number or another justified denominator, because cytotoxicity and proliferation differences can distort concentration-based comparisons.

Phagocytosis, Efferocytosis, and Tissue Crosstalk

Macrophage function in lesions extends beyond inflammatory mediator production. Uptake of particles, microbes, lipoproteins, and dying cells can engage different receptors and downstream programs. A generic phagocytosis assay cannot substitute for an efferocytosis assay, and neither necessarily predicts hemoglobin or lipid handling. The cargo should therefore match the disease question, and uptake should be separated from surface binding through imaging, quenching, or temperature controls.

Co-culture models can reveal consequences that are invisible in monoculture. Endothelial cells can report changes in adhesion, permeability, or inflammatory activation; vascular smooth-muscle cells can report phenotype switching and matrix production; fibroblasts can report remodeling signals; and platelets can provide a dynamic source of CXCL4 and other mediators. Conditioned-medium experiments distinguish soluble signaling from contact-dependent effects, while transwell and direct-contact formats address different mechanisms.

M4 Macrophages in Atherosclerosis

Atherosclerosis is the principal disease context in which M4 macrophages have been investigated. Human plaques contain heterogeneous myeloid populations shaped by lipids, cell death, hypoxia, hemorrhage, cytokines, platelets, vascular cells, and local anatomy. Histologic studies have identified macrophages with an M4-associated CD68-positive, MMP7-positive, S100A8-positive, and CD163-low or negative pattern in human lesions, supporting the idea that a CXCL4-related state can occur in vivo.

The biological interpretation remains nuanced. Colocalization of several proteins supports a phenotype, but it does not prove that CXCL4 alone created the cells or that all cells with those proteins share the same function. Human plaque samples also represent a time-integrated endpoint. Medication, comorbidities, lesion stage, vascular bed, tissue processing, and sampling depth can change the observed population. Claims about abundance or clinical association should therefore be tied to a defined cohort and validated with independent methods.

Single-cell and spatial technologies have transformed the description of plaque macrophages, revealing multiple inflammatory, resident-like, interferon-responsive, lipid-associated, foamy, and remodeling states. These data do not always produce a cluster labeled "M4," partly because cluster names depend on tissue composition, analytical resolution, and the reference signatures used. A productive strategy is to score a prespecified CXCL4/M4 gene module across cells, test its relationship to platelet-rich or CXCL4-rich regions, and confirm the result at the protein and functional levels.

M4 research can therefore contribute to three distinct questions. First, it can test whether CXCL4 is sufficient or necessary for a defined macrophage program. Second, it can determine where M4-like cells reside within lesions and which neighboring cells or structures are associated with them. Third, it can examine whether the program predicts matrix remodeling, impaired scavenging, lipid handling, plaque instability, or response to a candidate intervention. Keeping these questions separate helps prevent descriptive evidence from being overextended into causation.

Experimental Models for M4 Macrophage Research

Primary Human Monocyte-Derived Macrophages

Primary human monocytes preserve donor variation and provide continuity with the foundational M4 literature. They are well suited to donor-matched polarization studies, dose-response experiments, pathway perturbation, and functional assays. The main challenges are limited cell number, variable differentiation efficiency, donor-to-donor heterogeneity, and sensitivity to serum and media lots. A prospective plan for donor number, technical replication, exclusion criteria, and mixed-effects analysis is essential.

Cell Lines, iPSC-Derived Cells, and Engineered Systems

Myeloid cell lines offer scalability and experimental control but may not reproduce primary-cell CXCL4 responses. They are most useful for assay development, reporter construction, or mechanistic screening followed by confirmation in primary cells. iPSC-derived macrophages provide a renewable human platform and support genetic perturbation, yet differentiation state and tissue fidelity must be benchmarked. Engineered receptor or pathway models can clarify mechanism, provided that overexpression artifacts and baseline differences are addressed.

Plaque Tissue and Spatial Analysis

Human tissue offers the strongest disease relevance but the least control over exposure history. Multiplex immunofluorescence, imaging mass cytometry, spatial transcriptomics, and carefully designed single-cell workflows can localize M4-associated features while preserving relationships to platelets, vessels, necrotic core, hemorrhage, and matrix. Tissue dissociation may selectively lose fragile or lipid-laden cells, so spatial and dissociated-cell methods should be viewed as complementary rather than interchangeable.

Disease-Relevant Co-Culture and Perturbation Models

A stepwise model-development strategy begins with a defined CXCL4 response in macrophage monoculture, adds one disease-relevant input at a time, and then advances to a more integrated co-culture. Candidate inputs include modified lipoproteins, hypoxia, heme, apoptotic cells, platelet releasate, endothelial activation, or extracellular matrix. Factorial designs can determine whether the combined response is additive, synergistic, or antagonistic. This is especially important because a plaque-like environment may suppress one M4 marker while preserving another function.

Customized M4 Macrophage Research Support

Creative Biolabs can assemble a customized workflow around the scientific question and the maturity of the program. Early-stage projects may require protocol feasibility, reference-state comparison, and marker-panel development. Mechanistic programs may add pathway perturbation, receptor or ligand blocking, and gene-expression analysis. Translational programs may prioritize donor coverage, disease-relevant co-culture, candidate screening, biomarker strategy, and orthogonal validation.

Relevant capabilities include macrophage polarization assay development, custom macrophage marker development, cytokine expression profiling, and phagocytosis capacity analysis. These modules can be combined with project-specific controls and orthogonal assays so that the final data package addresses identity, mechanism, and function rather than relying on a single descriptive endpoint.

For studies centered on tissue remodeling or delivery, the workflow may also incorporate macrophage-fibroblast interaction analysis or macrophage-targeted drug delivery system development. Link selection should follow the biological hypothesis: a fibrosis-oriented program needs a different model and endpoint hierarchy from a vascular lipid-handling or target-engagement program.

What an M4 Macrophage Study Can Help You Answer

• Does CXCL4 induce a reproducible macrophage state in the selected donor population or model system?
• Which combination of markers most reliably separates M(CXCL4) cells from baseline, M1-like, and M2-like controls?
• Is CD163 downregulation accompanied by altered hemoglobin-haptoglobin uptake or heme handling?
• Does CXCL4 change lipid uptake, cholesterol efflux, foam-cell formation, or survival under atherogenic stress?
• Are MMP7, S100A8, secreted mediators, or proteolytic activity linked to a functional remodeling phenotype?
• Which signaling nodes are required for the state, and can a candidate drug or biologic prevent or reverse it?
• How do platelets, endothelial cells, smooth-muscle cells, fibroblasts, lipids, or hypoxia reshape the CXCL4 response?
• Is an M4-associated signature detectable in human tissue, and where is it located relative to disease anatomy?

Related Products

Q & A

Q: What defines an M4 macrophage?

A: An M4 macrophage is operationally defined as a CXCL4-conditioned macrophage state supported by a characteristic multiparameter profile. CD163 downregulation is historically important, and MMP7 and S100A8 are often included, but no single marker is sufficient. The inducing condition, comparator states, broader molecular signature, and at least one relevant function should be considered together.

Q: Are M4 macrophages the same as M1 macrophages?

A: No. M4 and M1-like macrophages can share selected inflammatory features, but the M4 state was defined by CXCL4 conditioning and has a distinct transcriptional and phenotypic profile. Direct comparison with standardized M1-like and M2-like controls is recommended rather than placing M4 on a simple linear scale.

Q: Which markers should be used to identify M4 macrophages?

A: A practical panel can include macrophage identity markers, reduced CD163, and M4-associated MMP7 and S100A8, together with markers that describe competing activation states. Marker direction and magnitude depend on donor, source, protocol, time, and tissue, so orthogonal RNA, protein, imaging, or functional confirmation is valuable.

Q: Can M4 macrophages be modeled with mouse cells?

A: Mouse models can be used to study CXCL4-dependent macrophage responses, but direct equivalence to the original human M4 definition should not be assumed. Cross-species work should compare conserved pathways and multigene modules and should validate key findings in a human system when translation is central.

Q: What functional assays are most informative for M4 studies?

A: The best assay follows the hypothesis. Options include hemoglobin-haptoglobin uptake, lipid uptake and cholesterol efflux, phagocytosis, efferocytosis, cytokine and chemokine release, protease activity, oxidative stress, and vascular-cell or fibroblast co-culture. A function linked to the disease question is more informative than marker classification alone.

Q: How should a candidate therapy be tested in an M4 model?

A: First establish a reproducible CXCL4-conditioned phenotype and prespecify the primary endpoint. Then test prevention and, when relevant, reversal designs with matched controls, concentration-response analysis, viability monitoring, target-engagement evidence, and confirmation in additional donors or a disease-relevant co-culture.

References

1. Fang, Fei, et al. "Tuning macrophages for atherosclerosis treatment." Regenerative biomaterials 10 (2023): rbac103. https://doi.org/10.1093/rb/rbac103
2. Distributed under Open Access license CC BY 4.0, without modification.